Insights Into HER2+ Breast Cancer

Perspectives on current treatment practices regarding HER2+ metastatic breast cancer, management of progressive HER2+ metastatic disease, and attitudes toward recently introduced and upcoming agents.

October 14, 2020
Purchase Report

Faculty Chair

Joyce A. O’Shaughnessy, MD

Texas Oncology-Baylor Charles A. Sammons Cancer Center, TX, US

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

Initial Treatment of HER2-Positive Advanced Breast Cancer

  • Overview of current data
    • Initial therapy
      • Impact of prior adjuvant therapy, disease-free interval, disease and patient characteristics
      • Is dual HER2 blockade the standard?
      • Which HER2-targeted agents?
      • Which chemotherapy partner?

Management of Progressive HER2-Positive Metastatic Disease

  • Overview of current data
    • Treatment of progressive disease
      • Newer agents (approved and in development)
        • Trastuzumab deruxtecan
        • T-DM1
        • Tucatinib
        • Neratinib
      • Management of emerging safety issues with HER2-directed therapies (pneumonitis, diarrhea, and interstitial lung disease)
      • Evolving guidelines for monitoring brain metastases

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • A moderated virtual roundtable discussion focusing on treatment of metastatic breast cancer was held October 14, 2020
  • The group of advisors comprised 9 community oncologists
  • Data collection was accomplished through use of audience response system questioning and moderated discussion

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.